Kahl, Klaus-Henning http://orcid.org/0000-0002-0545-1367
Shiban, Ehab
Gutser, Susanne
Maurer, Christoph J.
Sommer, Björn
Müller, Heiko
Konietzko, Ina
Grossert, Ute
Berlis, Ansgar
Janzen, Tilman
Stüben, Georg
Funding for this research was provided by:
Universität Augsburg
Article History
Received: 23 April 2022
Accepted: 30 August 2022
First Online: 23 September 2022
Declarations
:
: K.-H. Kahl received speaker honoraria and travel grants from ELEKTA AB, Varian Medical Systems, Carl Zeiss Meditec AG, AstraZeneca, Bristol Myers Squibb, MSD, Merck, and Medical Intelligence Medizintechnik, and is member of the advisory board of Bristol Myers Squibb, MSD, and AstraZeneca. E. Shiban, S. Gutser, C.J. Maurer, B. Sommer, H. Müller, I. Konietzko, U. Grossert, A. Berlis, T. Janzen, and G. Stüben declare that they have no competing interests.
: The ethics committee of the Ludwig Maximilian University of Munich (PNR 22-0156) approved the treatment protocol. It consists of experts of all medical disciplines involved and conforms to the provisions of the Declaration of Helsinki in 1995 (as revised in Edinburgh in 2000). The statistical analysis was performed using anonymous clinical data.